Coriolis PharmaMore than 600 customers trust the expertise of Coriolis. We develop liquid and lyophilized formulations out of one hand: no subcontracting to third parties. For each individual project, our highly skilled scientists develop tailor-made study designs that align with our customers’ drug development strategy. We do not force your molecule through an existing platform but create knowledge-driven innovative solutions. Our formulation services support all phases of drug development and our customers rely on Coriolis for trouble-shooting, batch-release analysis and formulation optimization even beyond market approval. We are specialized in:
· Pre-formulation and candidate selection
· Early stage formulation development
· Late phase formulation development
· Lyophilization cycle optimization
· Scale – up and transfer studies
· Developability / manufacturability assessment
· Support in container closure system selection
· In-use stability studies
· Stability testing including forced degradation studies
· R&D and cGMP-compliant contract analytical services
· Orthogonal analysis of subvisible aggregates and particles
Coriolis can draw from a unique analytical portfolio of more than 100 different techniques – entirely performed in-house – to obtain orthogonal and meaningful data. We offer all our services under Biosafety level 1 by default and a large selection also under Biosafety level 2. Dedicated GMP facilities with full involvement of Quality Management enable us to conduct lot-release analysis and generate supportive data for market approval and allow for tailored “enhanced R&D” level studies (e.g., qualified equipment but no QA involvement). Coriolis provides state-of-the-art as well as promising new and emerging technologies in the field of:
· Particle characterization (from nanometer to visible)
· Aggregate analytics
· Surfactant characterization
· Higher order structure analysis
· Chemical changes
